Screener
Ginkgo Bioworks DNA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 8) | 6 | 6 |
| Additional paid-in capital | 6,698,945 | 6,657,053 |
| Accumulated deficit | (6,279,617) | (6,150,320) |
| Accumulated other comprehensive income | 950 | 1,851 |
| Total stockholders’ equity | 420,284 | 508,590 |
| Total liabilities and stockholders’ equity | $990,046 | $1,119,696 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's total liabilities & equity?
- Ginkgo Bioworks (DNA) reported total liabilities & equity of $990.05M in Q2 2026.
- How has Ginkgo Bioworks's total liabilities & equity changed year-over-year?
- Ginkgo Bioworks's total liabilities & equity decreased by 19.6% year-over-year, from $1.23B to $990.05M.
- What is the long-term trend for Ginkgo Bioworks's total liabilities & equity?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's total liabilities & equity has grown at a 10.6% compound annual growth rate (CAGR), from $675.15M to $1.12B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Ginkgo Bioworks's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude